Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Soiken HoldingsTSE:2385 +1.40%58 5-Year Yield-on-Cost % is 4.65 as of Jul. 28, 2026, which is 301% above its 10-year median of 1.16. GuruFocus rates TSE:2385 with a GF Score™ of 58/100 and a GF Value™ of 円93.79 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, Soiken Holdings ranks better than 76% on this metric.
Soiken Holdings's yield on cost for the quarter that ended in Dec. 2025 was 4.65.
The historical rank and industry rank for Soiken Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
TSE:2385'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.11 Med: 1.16 Max: 4.65
Current: 4.65
During the past 13 years, Soiken Holdings's highest Yield on Cost was 4.65. The lowest was 0.11. And the median was 1.16.
TSE:2385's 5-Year Yield-on-Cost % is ranked better than 76% of 150
companies
in the Biotechnology industry
Industry Median: 1.695
vs TSE:2385: 4.65
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Soiken Holdings 5-Year Yield-on-Cost % Related Terms
TSE:2385 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Soiken Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soiken Holdings 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soiken Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Soiken Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Soiken Holdings is calculated as
Soiken Holdings (TSE:2385) has a 5-Year Yield-on-Cost % of 4.65 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Soiken Holdings and its competitors. This is 301% above median its historical median of 1.16. Over the past decade, Soiken Holdings' 5-Year Yield-on-Cost % has ranged from 0.11 to 4.65. According to the industry distribution chart, Soiken Holdings ranks #36 out of 150 companies in the Biotechnology industry, placing it in the top 24%.
Is Soiken Holdings' 5-Year Yield-on-Cost % too high?
Soiken Holdings' current 5-Year Yield-on-Cost % of 4.65 is 301% above median its 10-year median of 1.16. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 4.65. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.70. Soiken Holdings' value of 4.65 is 174.3% above this industry median. Based on the distribution chart, Soiken Holdings ranks #36 out of 150 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Soiken Holdings has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Soiken Holdings ranks #36 out of 150 companies for 5-Year Yield-on-Cost %. This places Soiken Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 1.70. Soiken Holdings' value of 4.65 is 174.3% above this benchmark. Historically, Soiken Holdings' own 5-Year Yield-on-Cost % has ranged from 0.11 to 4.65 over the past decade. While the company's 10-year median is 1.16 vs. the industry median of 1.70, Soiken Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Soiken Holdings's current 5-Year Yield-on-Cost % of 4.65 is 174.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Soiken Holdings and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Soiken Holdings's current 5-Year Yield-on-Cost % is 4.65, which is 301% above median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円93.79, compared to a current price of 円218.00 — trading 132.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 4.65, which is 301% above median its 10-year median of 1.16 and 174.3% above the Biotechnology industry median of 1.70. Soiken Holdings' overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current 5-Year Yield-on-Cost % is 4.65 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soiken Holdings (TSE:2385) Overvalued in 2026?
Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued.
The current stock price of 円218.00 is trading 132.4% above its estimated GF Value™ of 円93.79.
GuruFocus considers Soiken Holdings to be Significantly Overvalued.
Key valuation signals for TSE:2385:
5-Year Yield-on-Cost %: 4.65 (301% above median its 10-year median of 1.16)
GF Value™: 円93.79 vs. price of 円218.00 (132.4% above fair value)
Industry Position: 174.3% above the Biotechnology median (#36 of 150)
No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
58GF Score
Get the complete analysis for TSE:2385
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2385 has been successfully added to your 
